STOCK TITAN

Nutriband Inc - NTRB STOCK NEWS

Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.

About Nutriband Inc.

Nutriband Inc. (NASDAQ: NTRB) is a pharmaceutical company headquartered in Oviedo, Florida, specializing in the development and commercialization of innovative transdermal drug delivery systems. The company’s primary focus lies in leveraging its proprietary AVERSA™ abuse-deterrent technology to address critical safety concerns in the pharmaceutical industry, particularly related to opioid medications. By integrating aversive agents into transdermal patches, Nutriband enhances safety by preventing the abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, such as opioids and stimulants.

Core Business and Technology

Nutriband’s flagship product under development is the AVERSA™ Fentanyl transdermal patch, which aims to become the world’s first abuse-deterrent opioid patch. This innovative technology incorporates aversive agents, such as denatonium benzoate (Bitrex®), to create a bitter taste that deters oral abuse and accidental exposure, particularly in children. The AVERSA™ platform technology is versatile and can be applied to other transdermal formulations, broadening its potential applications in the pharmaceutical market.

The company operates within a robust intellectual property framework, with patents granted in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, and Australia. This extensive portfolio underscores Nutriband’s commitment to securing its technological innovations on a global scale.

Revenue Streams and Market Reach

Nutriband generates revenue through multiple channels, including the sale of consumer transdermal and coated products, as well as contract manufacturing services provided by its subsidiary, Pocono Pharma. Pocono Pharma specializes in kinesiology tape manufacturing and serves major retail clients, such as Target, Walmart, Walgreens, and CVS. This diversification not only strengthens Nutriband’s financial foundation but also positions it as a trusted partner in the manufacturing of specialized consumer healthcare products.

Industry Context and Competitive Position

Nutriband operates at the intersection of the pharmaceutical and healthcare industries, addressing critical challenges such as the opioid crisis and medication safety. The company’s AVERSA™ technology aligns with growing regulatory and societal demand for safer drug delivery systems. By focusing on transdermal solutions, Nutriband differentiates itself from competitors that primarily rely on traditional oral or injectable drug formulations. Its partnership with Kindeva Drug Delivery, a leading contract development and manufacturing organization, further enhances its capabilities in scaling and commercializing its products.

Intellectual Property and Global Expansion

With patents issued in major global markets, Nutriband has established a strong foundation for international expansion. Recent advancements include the extension of its intellectual property to regions such as Hong Kong and Macao, further solidifying its presence in Asia. These developments position Nutriband as a leader in the abuse-deterrent pharmaceutical space, capable of addressing both regional and global market needs.

Commitment to Innovation and Patient Safety

At its core, Nutriband is driven by a mission to enhance patient safety through innovative technologies. The AVERSA™ platform not only addresses the risks associated with opioid misuse but also ensures that essential medications remain accessible to patients who need them. This dual focus on safety and accessibility underscores Nutriband’s role as a socially responsible player in the pharmaceutical industry.

Conclusion

In summary, Nutriband Inc. is a pioneering company in the field of transdermal drug delivery, leveraging its proprietary AVERSA™ technology to address pressing healthcare challenges. With a diversified revenue model, strong intellectual property portfolio, and strategic partnerships, Nutriband is well-positioned to make a meaningful impact in the pharmaceutical and healthcare industries.

Rhea-AI Summary
Nutriband Inc. (NTRB) is set to present at The Microcap Conference in Atlantic City from January 30th to February 1st. CEO Gareth Sheridan will deliver two presentations and address questions. The company aims to showcase its potential to investors and traders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
conferences
-
Rhea-AI Summary
Nutriband Inc. CEO Gareth Sheridan published a letter to shareholders outlining the company's achievements in 2023 and targets for 2024. The company made significant strides in developing transdermal pharmaceutical products, securing new IP, and signing a commercial development and clinical supply agreement with Kindeva Drug Delivery for AVERSA Fentanyl, estimated to potentially reach peak annual sales of $80M - $200M. The company also reported strong revenue growth in 2023 and aims to expand its revenue opportunities through marketing initiatives and new product launches in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. (NTRB) announced a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with Kindeva Drug Delivery. The agreement aims to support a New Drug Application (NDA) with the FDA, replacing a previous feasibility agreement. Aversa™ Fentanyl is estimated to have the potential to reach peak annual US sales of $80M - $200M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.14%
Tags
none
Rhea-AI Summary
Nutriband Inc. (NTRB) launches Heating and Cooling Kinesiology Tape under AI Tape brand, offering pain-relieving ingredients for temporary relief of minor aches and pains. The product is the second launch this year, manufactured in the USA at Nutriband's facility in North Carolina, and available for purchase on Amazon and Activeintell.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.72%
Tags
AI
-
Rhea-AI Summary
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announces supplier agreement with KT Tape, a market leading kinesiology tape company, for a new line of specialized KT tape. The agreement showcases Nutriband's manufacturing capabilities and positions the company to develop innovative new product technologies with one of the world's largest brands, KT Tape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
none
-
Rhea-AI Summary
Nutriband completes market assessment and commercialization strategy for Aversa Buprenorphine transdermal system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
Rhea-AI Summary
Nutriband Inc. expands patent portfolio for AVERSA™ transdermal abuse deterrent technology, potentially reaching peak annual U.S. sales of $80M - $200M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. has been shortlisted for 5 awards at the Pharma Industry Awards 2023, recognizing their innovative development of AVERSA abuse-deterrent transdermal technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.18%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. reports a 48% increase in Q2 2023 revenues compared to Q2 2022, with quarterly revenue of $655,928. Stockholders' equity is $6.9 million as of July 31, 2023. The launch of AI Tape brand and partnership with Donovan McNabb as brand ambassador are seen as positive milestones for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.78%
Tags
Rhea-AI Summary
Nutriband engages Donovan McNabb as brand ambassador for AI Tape, targeting the $236M Elastic Therapeutic Tape market. McNabb's reputation as a pro athlete will deliver exposure and value to the brand. Global market expected to grow to $733.21M by 2033 with a CAGR of 12.0%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI

FAQ

What is the current stock price of Nutriband (NTRB)?

The current stock price of Nutriband (NTRB) is $6.88 as of March 3, 2025.

What is the market cap of Nutriband (NTRB)?

The market cap of Nutriband (NTRB) is approximately 78.9M.

What is Nutriband Inc.'s primary focus?

Nutriband Inc. focuses on developing transdermal pharmaceutical products, including its AVERSA™ abuse-deterrent technology, to enhance medication safety.

What is AVERSA™ technology?

AVERSA™ is Nutriband's proprietary abuse-deterrent technology that incorporates aversive agents into transdermal patches to prevent misuse, diversion, and accidental exposure of drugs.

How does Nutriband generate revenue?

Nutriband generates revenue through product sales, including transdermal and coated products, and contract manufacturing services via its subsidiary, Pocono Pharma.

What is the significance of Nutriband's intellectual property portfolio?

Nutriband holds patents in 46 countries, providing a strong foundation for global expansion and protecting its innovative AVERSA™ technology.

Who are Nutriband's strategic partners?

Nutriband collaborates with Kindeva Drug Delivery, a leading contract development and manufacturing organization, to scale and commercialize its products.

What problem does Nutriband aim to solve?

Nutriband addresses the opioid crisis and medication safety by developing abuse-deterrent transdermal patches that prevent misuse and accidental exposure.

What is Nutriband's flagship product?

Nutriband’s flagship product is the AVERSA™ Fentanyl patch, designed to be the world’s first abuse-deterrent opioid transdermal patch.

What industries does Nutriband operate in?

Nutriband operates in the pharmaceutical and healthcare industries, focusing on drug delivery systems and contract manufacturing.
Nutriband Inc

Nasdaq:NTRB

NTRB Rankings

NTRB Stock Data

78.85M
3.30M
54.05%
2.38%
0.5%
Biotechnology
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
ORLANDO